spacer
home > pmps > summer 2018 > the race to market
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Race to Market

The development of a new drug product therapy is a complex process that requires careful planning and meticulous execution. Even with these prerequisites, it can result in long lead times, high costs, and immense risks, with development timelines often exceeding 10 years from discovery to regulatory approval. For combination products, the process of bringing a product to market is complicated further. With growing competition in the market of injectable products, drug delivery systems have become increasingly important for the patient, caregiver, and healthcare professionals in terms of ease of use as well as product differentiation. These factors require pharmaceutical and biotechnology companies to identify a strategy for a drug delivery system early in the drug development phase to effectively and efficiently bring the combination product to market.

As the expert that understands the intricacies of the self-injection process and the complexities of the combination product development timelines, a device developer is often contracted to help companies maximise investments and minimise potential delays to commercial launch. Combining this knowledge and experience with a strong set of in-house capabilities, the development process can often be expedited, ultimately ensuring the successful commercialisation of the combination product in a timely manner.

Of Primary Importance

An auto-injector consists of a drugcontaining primary container and a device containing many moving parts and mechanical forces specifically designed to ensure that the drug product is fully injected within the specified delivery requirements. Both the drug product and device are highly regulated components, and the efforts to deliver the drug safely and effectively is an undertaking that requires close collaboration between the company and the device developer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Taras Seniuch is Director of Business Development at SHL Group: designer, developer, and manufacturer of advanced drug delivery devices such as auto-injectors and pen injectors. With over 17 years of experience within the pharma and medical device industry, Taras leads the business development efforts for the CMO, SHL Pharma, which provides assembly and secondary packaging solutions for SHL-designed devices for pharma and biotech products.
spacer
Taras Seniuch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services (PPS) reaches new level in characterizing HCP protein impurities

In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q Exactive™ HF-X started operational service last month and brings PPS to the next level of reproducible, accurate and sensitive analyses of majorly complex samples for different aspects of translational research and biopharma applications.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.

Medpace

Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement